The hydroethanolic extract of Crataegus monogyna was studied for its chemical constitution and angiotensin-converting enzyme (ACE) inhibitory activity. The extract contained triterpenic acids, flavonoids and coumarins. The ACE inhibitory activity was studied using captropril, as a control drug, and oleanolic acid, as a constituent of the hydroethanolic extract and a member of the triterpenic acid group. The hydroethanolic extract and oleanolic acid showed higher IC50 values (335.00 μg/mL and 3.61 μM, respectively) in comparison to captopril (46.9 nM). However, these results indicate the anti-ACE activity of oleanolic acid and the triterpenic acids, which has not been demonstrated earlier for hawthorn extracts. In previous studies, the ACE inhibitory activity of C. monogyna extracts was always attributed to flavonoids and proanthocyanidins.
AmmonHP, HandelM. (1981) Crataegus, Toxikologie und Pharmakologie, teil I: Toxizitat. Planta Medica, 43, 105–120.
4.
NetienMG (1963) Characterisation of pharmaceutical preparations from hawthorn base by pper cromatography. Bulletin des Travaux de la Société Pharmacie, 7, 145–153.
5.
CipleaAG, RichterKD. (1988) The protective effect of Allium sativum and Crataegus on isoprenaline-induced tissue necroses in rats. Arzneimittel Forschung, 38, 1583–1592.
6.
WeiklA, AssmusKD, SchmidtA, SchmitzJ, ZapfeG, NohHS, SiegristJ. (1996) Crataegus special extract WS 1442: assessment of objective effectiveness in patients with heart failure. Fortschritte der Medizin, 114, 291–296.
7.
JosephG, ZhaoY, KlausW. (1995) Pharmacological profile of Crataegus extract compared to epinephrine, amrinone, milrinone and digoxin in isolated Guinea pig hearts, Arzneimittel Forschung, 45, 1261–1265.
8.
ShantiS, ParasakthyK, DeepalakshmiPD, DevarajS, NiranjaliS. (1994) Hyperlipidaemic activity of tincture of Crataegus in rats. Indian Journal of Biochemistry and Biophysiology, 31, 43–146.
9.
PetkovV. (1979) Plants and hypotensive, antiatheromatous and coronarodilatating action. American Journal of Chinese Medicine, 7, 197–236.
10.
SchimertG, BlömerH (1953) Beitrag zur Pharmakologie der Crataegus-Wirkstoffe. über die Kreislaufwirkung der Triterpensäuren. Archiv für Experimentelle Pathologie und Pharmakologie, 217, 337.
11.
MorigiwaA, KitabatakeK, FujimotoY, IkekawaN. (1986) Angiotensin converting enzyme-inhibitory triterpenes from Ganoderma lucidum. Chemical & Pharmaceutical Bulletin, 34, 3025–3028.
MoawadMA. (2005) The need for evidence in hypertension management: historical perspective. Annals of Saudi Medicine, 25, 367–374.
17.
SturmHB, Haaijer-RuskampFM, VeegerNJ, Balje-VolkersCP, SwedbergK, van GilstWH. (2006) The relevance of comorbidities for heart failure treatment in primary care: A European survey. European Journal of Heart Failure, 8, 31–37.
18.
GuptaM, LonnEM, VermaS. (2005) Should patients with stable coronary artery disease be treated with ACE inhibitor therapy?Nature Clinical Practice Cardiovascular Medicine, 2, 124–125.
19.
SeguraJ. (2004) Blocking the renin-angiotensin system in chronic kidney disease. Nefrologia, 24, 187–235 [Spanish].
20.
CushmanDW, CheungHS. (1971) Spectrophotometric assay and properties of the angiotensin converting enzyme of rabbit lung. Biochemical Pharmacology, 20, 1637–1648.
21.
SchnaithE, BeyrauR, BucknerB, KleinRM, RickW. (1994) Optimized determination of angiotensin I-converting enzyme activity with hippuryl-L-histidyl-L-leucine as substrate. Clinica Chimica Acta, 227, 145–158.
22.
HeG, XuanG, RuanH, ChenQ, XuY. (2005) Optimization of angiotensin I-converting enzyme (ACE) inhibition by rice dregs hydrolysates using response surface methodology. Journal of Zhejiang University Science, 6B, 508–513.
23.
MehannaAS, DowlingM. (1999) Liquid chromatographic determination of hippuric acid for the evaluation of ethacrynic acid as angiotensin-converting enzyme inhibitor. Journal of Pharmaceutical and Biomedical Analysis, 19, 967–973.
24.
HolmquistB, BünningP, RiordanK. (1979) A spectrophotometric assay for ACE. Analytical Biochemistry, 95, 540–544.
25.
MurrayBA, WalshDJ, FitzGeraldRJ. (2004) Modification of the furanacryloyl-L-phenylalanylglycylglycine assay for determination of angiotensin I-converting enzyme inhibitory activity. Journal of Biochemical and Biophysical Methods, 59, 127–137.
26.
EricksonJA, CousinR, WuJT, AshwoodER. (2003) Quantitative spectrophotometric microplate assay for angiotensin-converting enzyme in cerebrospinal fluid. Clinical Chemistry, 49, 70–72.
27.
LeeMH, LinYS, LinYH, HsuFL, HouWC. (2003) The mucilage of yam (Dioscorea batatas Decne) tuber exhibited angiotensin converting enzyme inhibitory activities. Botanical Bulletin of Academia Sinica, 44, 267–273.
28.
ElblG, WagnerH. (1991) A new method for the in vitro screening of inhibitors of angiotensin-converting enzyme (ACE), using the chromophore- and fluorophore-labelled substrate, dansyltriglycine. Planta Medica, 57, 137–41.
29.
OcchiutoF, CircostaC, BriguglioF, TommasiniA, De PasqualeA. (1986) étude comparée de l’ activité cardiovasculaire de jeunes, pousses des feuilles et des fleurs de Crataegus oxyacantha L. I. Activité électrique et tension artérielle chez le rat. Plantes Médicinales et Phytothérapie, 20, 37–51.
30.
OcchiutoF, CircostaC, CostaR, BriguglioF, TommasiniA. (1986) étude comparée de l’ activité cardiovasculaire de pousses des feuilles et des fleurs de Crataegus oxyacantha L. II. Action de préparations extractives et de principes actifs purs isolés sur le coeur isolé du lapin. Plantes Médicinales et Phytothérapie, 20, 52–63.
31.
HerfindalET, GourleyDR, HartLL. (1992) Clinical Pharmacy and Therapeutics, Williams and Wilkins, USA, 1–1628.
32.
VermeirssenV, Van CampJ, VerstraeteW. (2002) Optimisation and validation of an angiotensin-converting enzyme inhibition assay for the screening of bioactive peptides. Journal of Biochemical and Biophysical Methods, 51, 75–87.
33.
CornellMJ, WilliamsTA, LamangoNS, CoatesD, CorvolP, SoubrierFt, HoheiselJ, LehrachH, IsaacRE. (1995) Cloning and expression of an evolutionary conserved single-domain angiotensin converting enzyme from Drosophila melanogaster. Journal of Biological Chemistry, 270, 13613–13619.
34.
CoulsonCJ. (1995). Molecular Mechanisms of Drug Action.Taylor and Francis Ltd.UK. 1–294.
35.
FujitaH, YoshikawaM. (1999) LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein. Immunopharmacology, 44, 123–127.
36.
TanGT, LeeS, LeeIS, ChenJ, LeitnerP, BesternmanJM, KinghornAD, PezzutoJM. (1996) Natural-product inhibitors of human DNA ligase I. Biochemical Journal, 314, 993–1000.
37.
HussU, RingbomT, PereraP, BohlinL, VasängeM. (2002) Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay. Journal of Natural Products, 65, 1517–1521.
38.
Caballero-GeorgeC, VanderheydenPML, OkamotoY, MasakiT, MbwamboZ, ApersS, GuptaMP, PietersL, VauquelinG, VlietinckA. (2004) Evaluation of bioactive saponins and triterpenoidal aglycons for their binding properties on human endothelin ETA and angiotensin AT1 receptors. Phytotherapy Research, 18, 729–736.
39.
YingQL, RinehartAR, SimonSR, CheronisJC. (1991) Inhibition of human leucocyte elastase by ursolic acid. Evidence for a binding site for pentacyclic triterpenes. Biochemical Journal, 277, 521–526.
40.
TegliaA. (1989) Studio dei procedimenti di estrazione di principi attivi di piante officinali. Caso della Calendula officinalis L., Cosmetics & Toiletries, 10, 28–53.
41.
JacobiH, OberdorfA, RummelW. (1956) Zur Frage der Coronarwirkung von Crataegus-Extrakten, Arzneimittel Forschung, 6, 98–99.
42.
HarborneJB. (1988) Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis.Chapman and Hall. London, UK, 1–288.
43.
WagnerH, BladtS. (1996) Plant Drug Analysis.Springer. München, Germany, 1–384.
44.
HayekT, PavlotzkyE, HamoudS, ColemanR, KeidarS, AviramM, KaplanM. (2003) Tissue Angiotensin-Converting-Enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 2090–2096.
45.
LanfrancoG. (1993) Ħxejjex medi⋅inali u Oħrajn fil-Gżejjer Maltin, Pubblikazzjoni Media Centre, Malta, 1–132.
